High dose dipyridamole echocardiography test in effort angina pectoris

The dipyridamole echocardiography test (intravenous dipyridamole with two-dimensional echocardiographic monitoring) was performed in 93 patients with effort chest pain and in 10 control subjects. The test was considered positive when regional asynergy appeared after dipyridamole administration. When negative at the low dose (0.56 mg/kg body weight in 4 minutes), the test was repeated on a different day with a higher dose (0.84 mg/kg in 10 minutes). All 93 patients underwent coronary arteriography; 72 of them had significant (greater than 70% luminal reduction) coronary artery disease. Thirty-eight of the 93 patients had a positive low dose dipyridamole echocardiography test; 15 other patients with a negative low dose test had a positive high dose test. All 53 patients with a positive test had significant coronary artery disease; 12 of them had a negative exercise stress test. In relation to the presence of coronary artery disease, the dipyridamole echocardiography test had an overall specificity higher than that of the exercise stress test (100 versus 71%) and a similar overall sensitivity (74 versus 69%). The dipyridamole echocardiography test is feasible in all patients with a good baseline echocardiogram. It detects the site of apparent ischemia more precisely than does an exercise stress test, and can unmask electrocardiographically silent ischemia. If performed in patients with a negative low dose dipyridamole echocardiography test, the high dose test adds sensitivity (probably by achieving maximal dilation in patients in whom the low dose is only partially effective), without any loss in specificity and with no apparent increase in risk.

This article has been cited by other articles:

				R. Sicari, P. Nihoyannopoulos, A. Evangelista, J. Kasprzak, P. Lancellotti, D. Poldermans, J.-U. Voigt, J. L. Zamorano, and on behalf of the European Association of Echocardi Stress Echocardiography Expert Consensus Statement--Executive Summary: European Association of Echocardiography (EAE) (a registered branch of the ESC) Eur. Heart J., February 1, 2009; 30(3): 278 - 289. [Full Text] [PDF]

				R. Sicari, P. Nihoyannopoulos, A. Evangelista, J. Kasprzak, P. Lancellotti, D. Poldermans, J.-U. Voigt, J. L. Zamorano, and on behalf of the European Association of Echocardi Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC) Eur J Echocardiogr, July 1, 2008; 9(4): 415 - 437. [Abstract] [Full Text] [PDF]

				T.-H. Park, N. Tayan, K. Takeda, H.-K. Jeon, M. A. Quinones, and W. A. Zoghbi Supine Bicycle Echocardiography: Improved Diagnostic Accuracy and Physiologic Assessment of Coronary Artery Disease With the Incorporation of Intermediate Stages of Exercise J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1857 - 1863. [Abstract] [Full Text] [PDF]

				M. G. Andreassi, N. Botto, A. Rizza, M. G. Colombo, C. Palmieri, S. Berti, S. Manfredi, S. Masetti, A. Clerico, and A. Biagini Deoxyribonucleic acid damage in human lymphocytes after percutaneous transluminal coronary angioplasty J. Am. Coll. Cardiol., September 4, 2002; 40(5): 862 - 868. [Abstract] [Full Text] [PDF]

				J A S. Román, I Vilacosta, J A Castillo, M J Rollán, M Hernández, V Peral, I Garcimartín, M d. M. de la Torre, and F Fernández-Avilés Selection of the optimal stress test for the diagnosis of coronary artery disease Heart, October 1, 1998; 80(4): 370 - 376. [Abstract] [Full Text]

				E. Picano and C. Michelassi Chronic oral dipyridamole as a 'novel' antianginal drug: the collateral hypothesis Cardiovasc Res, March 1, 1997; 33(3): 666 - 670. [Abstract] [PDF]

				R. M. Fleming, C. H. Rose, and K. M. Feldmann Comparing a High-Dose Dipyridamole SPECT Imaging Protocol with Dobutamine and Exercise Stress Testing Protocols Angiology, July 1, 1995; 46(7): 547 - 556. [Abstract] [PDF]

				A.M. Cicatiello, P. Landino, P. Simonelli, L. Del Mastro, P. Ferrara, A. Cioppa, and F. Ciaburri Safety of Echo-Dipyridamole Test in Elderly Patients with Coronary Artery Disease Angiology, April 1, 1995; 46(4): 321 - 326. [Abstract] [PDF]

				M. M. Gulizia, P. Lo Giudice, G. Doria, R. Valenti, and A. G. Circo Hypertension and Ischemic Heart Disease Role of Dipyridamole Echocardiography Test Angiology, November 1, 1994; 45(11): 943 - 948. [Abstract] [PDF]

				T. W. Martin, J. F. Seaworth, J. P. Johns, L. E. Pupa, and W. R. Condos Comparison of Adenosine, Dipyridamole, and Dobutamine in Stress Echocardiography Ann Intern Med, February 1, 1992; 116(3): 190 - 196. [Abstract] [PDF]

				H. G. Stratmann, D. L. Janosik, L. E. Mezei, A. L. Mark, and G. A. Williams Atrial Pacing with Two-Dimensional Echocardiography for Evaluation of Chest Pain: Comparison with Thallium 201 Scintigraphy Angiology, November 1, 1991; 42(11): 855 - 865. [Abstract] [PDF]

				T. Konishi, T. Koyama, T. Aoki, Y. Futagami, and T. Nakano Dipyridamole Radionuclide Ventriculography in Patients with Coronary Artery Disease: Comparison with Ergometer Exercise Angiology, July 1, 1990; 41(7): 518 - 524. [Abstract] [PDF]